secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000950170-24-118988
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin Q3 net revenue $42.3M (-36% YoY); European revenue grows, U.S. declines on generic competition
--------------------------------------------------------------------------------

- Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.
- European net product revenue $4.3M (up from $0.8M); VAZKEPA sales grew 19% sequentially in Spain and UK.
- Net loss $25.1M ($0.06/share) vs $19.3M loss ($0.05); non-GAAP adjusted net loss $20.4M ($0.05).
- Cash and investments $305.7M, flat QoQ; reaffirms cash adequate for foreseeable future.
- Company committed to maintaining public listing; exploring paths to resolve issue. Virtual Analyst Day Nov 14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017024118988/0000950170-24-118988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017024118988/amrn-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-118988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer